About
Preserved Ejection Fraction Heart Failure Treatment
CorAssist is a clinical-stage medical device company developing therapeutic products for treating heart failure with preserved ejection fraction. The companys proprietary technology enables the implantation of a device that directly improves cardiac diastolic function. CORolla is an elastic, self-expanding, internal, spring-like device implanted inside the left ventricle through a transapical or percutaneous procedure. The device assists diastolic function by improving diastolic dynamics and filling performance, and does not require an external power source. ImCardia, the companys first product, is an elastic, self-expanding device that is attached to the external left ventricular surface through a simple off-pump procedure.
Identity
| Name | CorAssist |
|---|---|
| Slug | corassist |
| Type / kind | startup |
| Crunchbase ID | corassist |
| Source _id | agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgJ6LoPwIDA |
Status
| Status | inactive |
|---|---|
| Status reason | Non Active, Dec 2022 ceased to operate |
| Last update | 2026-05-17 |
Location
| HQ country code | IL |
|---|---|
| HQ region/district | North District |
| HQ city | Haifa |
| HQ address | Derech HaAtsma'ut 57, Haifa, Israel |
Web & social
| https://www.linkedin.com/company/151987 |
Classifications
Funding
| Total raised | $14.5M |
|---|---|
| Current stage | Series B |
Raw source document
Show full JSON (0 KB)
{
"0": "s",
"1": "l",
"2": "i",
"3": "m",
"4": "p",
"5": "a",
"6": "g",
"7": "e",
"8": "s",
"9": "_",
"10": "i",
"11": "m",
"12": "p",
"13": "o",
"14": "r",
"15": "t"
}